Key Points
- Haleon insider Blathnaid Bergin bought 7,670 shares at GBX 324 each, investing approximately £24,851.
- Haleon’s board approved a £500 million share repurchase program, allowing the company to buy back up to 1.8% of its outstanding shares.
- Analyst sentiment is mixed: Haleon has an overall “Hold” consensus rating and an average price target of GBX 356, compared with a share price near GBX 323.
Haleon plc (LON:HLN - Get Free Report) insider Blathnaid Bergin bought 7,670 shares of the stock in a transaction that occurred on Friday, October 30th. The stock was acquired at an average price of GBX 324 per share, for a total transaction of £24,850.80.
Haleon Price Performance
Shares of LON HLN opened at GBX 323.20 on Tuesday. Haleon plc has a fifty-two week low of GBX 310.50 and a fifty-two week high of GBX 433.60. The stock has a market cap of £28.43 billion, a price-to-earnings ratio of 17.86, a PEG ratio of 1.49 and a beta of 0.24. The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69. The firm's 50-day simple moving average is GBX 352.17 and its 200 day simple moving average is GBX 360.21.
Haleon announced that its Board of Directors has approved a share repurchase program on Thursday, October 29th that authorizes the company to repurchase £500 million in shares. This buyback authorization authorizes the company to repurchase up to 1.8% of its stock through open market purchases. Share buyback programs are generally an indication that the company's management believes its stock is undervalued.
Analysts Set New Price Targets
Several research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised Haleon to a "hold" rating and cut their target price for the company from GBX 320 to GBX 310 in a research report on Friday. Berenberg Bank lowered their price target on Haleon from GBX 514 to GBX 365 and set a "buy" rating for the company in a research report on Monday. Jefferies Financial Group reissued a "buy" rating and issued a GBX 400 price target on shares of Haleon in a research report on Friday. Finally, Royal Bank Of Canada raised their price objective on Haleon from GBX 370 to GBX 390 and gave the company a "sector perform" rating in a research note on Tuesday, August 11th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of GBX 356.
Get Our Latest Research Report on Haleon
About Haleon
(
Get Free Report)
Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
